Zacks Investment Research
05 Aug 2026, 12:46 UTC · 1h ago
United Therapeutics (UTHR) Q2 Earnings Surpass Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 12:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
United Therapeutics reported quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82. — An earnings beat typically drives positive sentiment and short-term price appreciation for the specific ticker.
+0.40United Therapeutics posted quarterly revenues of $783.3 million, missing the Zacks Consensus Estimate by 2.51%. — A revenue miss suggests slowing top-line growth, which can offset the positive impact of an earnings beat.
-0.30Which stocks this story touches
The company beat quarterly earnings estimates, although it missed revenue estimates.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
